A Phase 1/2 interventional study of Netarsudil Ophthalmic in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Massachusetts Eye and Ear Infirmary. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Massachusetts Eye and Ear Infirmary · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Vitreoretinopathy, Proliferative with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Vitreoretinopathy, Proliferative · United States.
Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 11th registered.
43 studies on the registry are indexed under Vitreoretinopathy, Proliferative; 11 are open to participants now.
Browse Vitreoretinopathy, Proliferative studies →2 of the 12 studies in Vitreoretinopathy, Proliferative with a site in United States are open now. Recruiting first, the newest first:
Cincinnati Eye Institute, Southwest Ohio · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Vitreoretinopathy, Proliferative studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 2 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 64 across 30 interventional studies indexed under Vitreoretinopathy, Proliferative.
Median enrollment 69 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
Massachusetts Eye and Ear Infirmary is the lead sponsor of 101 studies on the registry; 24 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Massachusetts Eye and Ear Infirmary has 2 studies filed under Vitreoretinopathy, Proliferative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes.
The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
This is an open-label, randomized study that will test the safety and pharmacokinetics of topical netarsudil at a dose frequency of once-daily in two cohorts of patients: those with primary rhegmatogenous detachments, and those with established proliferative vitreoretinopathy. The intervention will be topical application of Netarsudil from time of diagnosis of retinal detachment to 16 weeks post-operatively.
Patients will be randomized to one of the following groups:
After surgery, patients will continue on once per day dosing of Netarsudil for a total of 16 weeks post-op.
The primary rhegmatogenous detachment cohort will have the following selection criteria:
Inclusion criteria:
Exclusion criteria:
The proliferative vitreoretinopathy cohort will have the following selection criteria:
Inclusion criteria:
Exclusion criteria:
Phakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.
Drug: Netarsudil Ophthalmic
Pseudophakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.
Drug: Netarsudil Ophthalmic
Phakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.
Drug: Netarsudil Ophthalmic
Pseudophakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.
Drug: Netarsudil Ophthalmic
Topical administration of Netarsudil
Also known as: Rhopressa
The concentration of netarsudil in the vitreous to assess its pharmacokinetic properties.
Netarsudil concentration in the posterior segment of the eye, using High-performance liquid chromatography (HPLC)
Time frame: Through study completion, an average of 1 year
Serious adverse events
Unexpected serious adverse events
Time frame: Day 1, 7, 28, 84, and 168 after surgery
Number of operations within 3 months
Total number of operation during the first 3 months after surgery
Time frame: Day 84 after surgery
Final attachment status at last follow-up
Status of the retina (attached versus detached) at last follow-up visit
Time frame: Day 168 after surgery
Visual acuity
Best-corrected visual acuity measured using Snellen chart
Time frame: Day 1, 7, 28, 84, and 168 after surgery
Spectral domain optical coherence tomography (SD-OCT) of the macula
Status of the macula (mac-on versus mac-off)
Time frame: Day 1, 7, 28, 84, and 168 after surgery
Adverse events
Adverse events including conjunctival injection, subconjunctival hemorrhage, and corneal verticillata, eye irritation, reticular edema of the cornea, hypotony
Time frame: Day 1, 7, 28, 84, and 168 after surgery
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Sep 2028, 43 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2026 → Sep 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil
Vitreoretinopathy, Proliferative →
Massachusetts Eye and Ear Infirmary →